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The effect of patient age at intervention on risk of implant 
revision after total replacement of the hip or knee: 
a population-based cohort study 
Lee E Bayliss, David Culliford, A Paul Monk, Sion Glyn-Jones, Daniel Prieto-Alhambra, Andrew Judge, Cyrus Cooper, Andrew J Carr, Nigel K Arden, 
David J Beard, Andrew J Price
Summary
Background Total joint replacements for end-stage osteoarthritis of the hip and knee are cost-effective and demonstrate 
significant clinical improvement. However, robust population based lifetime-risk data for implant revision are not 
available to aid patient decision making, which is a particular problem in young patient groups deciding on best-
timing for surgery.
Methods We did implant survival analysis on all patients within the Clinical Practice Research Datalink who had 
undergone total hip replacement or total knee replacement. These data were adjusted for all-cause mortality with data 
from the Office for National Statistics and used to generate lifetime risks of revision surgery based on increasing age 
at the time of primary surgery.
Findings We identified 63 158 patients who had undergone total hip replacement and 54 276 who had total knee 
replacement between Jan 1, 1991, and Aug 10, 2011, and followed up these patients to a maximum of 20 years. For 
total hip replacement, 10-year implant survival rate was 95·6% (95% CI 95·3–95·9) and 20-year rate was 85·0% 
(83·2–86·6). For total knee replacement, 10-year implant survival rate was 96·1% (95·8–96·4), and 20-year implant 
survival rate was 89·7% (87·5–91·5). The lifetime risk of requiring revision surgery in patients who had total hip 
replacement or total knee replacement over the age of 70 years was about 5% with no difference between sexes. For 
those who had surgery younger than 70 years, however, the lifetime risk of revision increased for younger patients, up 
to 35% (95% CI 30·9–39·1) for men in their early 50s, with large differences seen between male and female patients 
(15% lower for women in same age group). The median time to revision for patients who had surgery younger than 
age 60 was 4·4 years.
Interpretation Our study used novel methodology to investigate and offer new insight into the importance of young 
age and risk of revision after total hip or knee replacement. Our evidence challenges the increasing trend for more 
total hip replacements and total knee replacements to be done in the younger patient group, and these data should be 
offered to patients as part of the shared decision making process.
Funding Oxford Musculoskeletal Biomedical Research Unit, National Institute for Health Research.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Hip and knee replacements have been routinely done for 
the treatment of end-stage arthritis over the past 40 years;1,2 
76 000 total hip replacements and 82 000 total knee 
replacements were done in 2014 in the UK alone,3 with the 
greatest increase in the number of total knee replacements 
in recent years. The outcomes of joint replacements are 
determined in several different ways, including mortality4,5 
and morbidity rates after surgery, functional outcome and 
satisfaction recorded as patient-reported outcome scores,6 
and by rates of failure of the implant leading to revision 
surgery.3,7 Total hip replacement and total knee replacement 
have demonstrated improved function,8 reduced pain, and 
improved quality of life9 for patients, and are cost-effective.9 
Predictions are that in the next 10–20 years primary joint 
replacement rates will substantially increase, not only as a 
consequence of an ageing population, but also because of 
increasing use in patients younger than age 60 years,10 who 
currently represent 15% of the entire population 
undergoing surgery, but might increase in the future.11
This rise in the number of patients younger than 60 years 
undergoing surgery is a concern because joint registries 
reveal that 10-year revision rates in this group are higher 
than for older age groups.3 For all patients, the decision to 
have surgery is largely based on the balance between 
potential risk and benefit. The James Lind Alliance Priority 
Setting Partnership, a public–patient involvement group, 
has established that the relation between timing of joint 
replacement and best outcome is one of the most 
significant concerns for patients with osteoarthritis. This is 
of particular importance in determining optimum timing 
for surgery in younger patients, where they can be expected 
to potentially outlive their primary replacement. Therefore, 
the length of time a joint replacement will last (before 
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requiring revision) becomes a major factor in deciding 
whether to proceed with surgery. The most widely used 
and quoted data for risk of revision come from joint 
registry reports, but are often limited to 10 years of follow-
up.3,7,12 Other studies with longer patient follow-up (greater 
than 20 years) are frequently restricted to specific 
prostheses or small populations, without specific focus on 
the results from patients younger than 60 years at 
implantation.13,14 Therefore, for these patients, information 
about implant revision rates tends to be restricted to 
10 years, and although worse than those seen for patients 
older than 60,3,9,15 might not truly reflect the risk of revision 
over the longer timeframe. The decision making process 
for younger patients is hence not fully informed, and could 
lead to inappropriate election to undergo joint 
replacement.15,16
There is a clear need for more representative long-term 
data that could be used to inform patients of the risk of 
revision surgery. One approach that has not previously 
been used comes from combining data from the Clinical 
Practice Research Datalink, a database that contains 
long-term data for joint replacement that spans over 
20 years, and adopting different methods of analysis that 
are new to this discipline. The notion of lifetime risk 
describes the probability (expressed as a percentage) of 
an event or disease occurring over the course of a 
lifetime. It has been used in oncology research, and 
infrequently in musculoskeletal literature,17–19 but has 
never been used to assess the lifetime risk of revision 
surgery after joint replacement. Lifetime risk data is 
useful to patients, clinicians, and health-care planners 
alike as it provides a simple idea to convey to patients and 
is easier to understand than time-dependent incidence 
rates (such as 10-year risk of revision),20 which are 
commonplace both in the explanation of revision risks to 
patients undergoing primary joint replacement and in 
the assessment of prosthesis longevity.3
The aim of this study was to determine age adjusted 
estimates of lifetime risk of undergoing a revision 
procedure after primary total hip replacement or total 
knee replacement with data from the Clinical Practice 
Research Datalink and Office for National Statistics.
Methods
Data Sources
Participant data were obtained from the Clinical 
Practice Research Datalink (CPRD), formerly known as 
the General Practice Research Database. The CPRD 
consists of the computerised primary care medical 
records of all patients attending a selection of general 
practitioners in the UK. This population of 6·5 million 
patients is taken from 433 contributing practices 
chosen to be representative of the wider UK population;21 
therefore the CPRD consists of entire general practice 
populations rather than probability-based samples of 
patients.
Each patient is registered at one practice, which stores 
both primary care and hospital episode information. The 
universal health-care system in the UK is dependent on 
primary care for referrals and funding of hospital 
episodes, and therefore the CPRD is a detailed record of 
both primary and secondary care. The CPRD dataset for 
each patient contains all clinical and referral events in 
both primary and secondary care, comprehensive 
demographic information, prescription data, and 
hospital admissions data. Data are stored with Read and 
Oxford Medical Information Systems (OXMIS) codes for 
diseases that are cross-referenced to the International 
Research in context
Evidence before this study
We searched Medline, Embase, and the Cochrane Library up to 
Nov 2015 for all studies investigating lifetime risk of revision 
in total hip and total knee replacement or arthroplasty. Whilst 
publications were identified for lifetime risk of undergoing 
primary joint replacement of the hip or knee, no such studies 
were found for lifetime risk of revision surgery. Review of 
National Joint Registries reports (England & Wales, Australia, 
New Zealand, Sweden, Norway, Denmark) revealed 
publication of annual survival incidences but not lifetime risk 
predictions.
Added value of this study
This study proposes the use of lifetime revision risk 
predictions, based on a large dataset, as a useful and novel 
tool for both clinicians and patients. Although data are 
available that describe the lifetime risk of need for primary 
joint replacement, data have not been published for revision 
risk following primary procedure. Before this study, revision 
rates have been quoted as survival incidences (usually at 
10 years) however the context of a 10-year revision risk is very 
different for young patients compared to those of greater 
age, for whom 10 years could represent the majority of their 
life-expectancy. This study allows patients to understand the 
risk in the context of their predicted life-expectancy, and as 
such, better inform their decision to undergo joint 
replacement surgery. 
Implications of all the available evidence
Previous study data, increasingly based upon national registers, 
showed that young patients are at a higher risk of revision than 
are older patients; this study expands upon this problem to 
better highlight how much greater this risk is over a patient’s 
lifetime and to put this into a statistic that is easier to explain to 
patients considering surgery. The number of younger patients 
undergoing joint replacement surgery is increasing and it is 
crucial that their decision to undergo surgery is based on best 
available, personalised evidence.
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Classification of Diseases (ICD-9). Read codes are used 
as the standard clinical terminology system within UK 
primary care. Only practices that pass quality control are 
used as part of the CPRD database. Deleting or encoding 
personal and clinic identifiers ensures confidentiality of 
information. The CPRD is administered by the Medicines 
and Healthcare Products Regulatory Agency (MHRA).
Population
All patients in the database with a diagnostic code for 
primary total hip or knee replacement from Jan 1, 1991, 
until Aug 10, 2011, were identified. Read/OXMIS codes 
were used to identify primary replacements and subsequent 
revision surgeries (appendix). Patients were included in the 
analysis if aged 50 years or over at the time of index primary 
joint replacement procedure. Participant demographics 
including age and sex were collated. Sex-specific all-cause 
mortality data was obtained from the Office for National 
Statistics (ONS)22 for Jan 2, 1991, to Dec 31, 2011.
Analysis
Data from the CPRD were aggregated into single 
year intervals by age at the time of index procedure 
(primary joint replacement) and then subdivided into hip 
or knee replacement, and by sex. Age was defined as age 
at last birthday, starting at 50 years; consistent definitions 
were applied to death data and timing of any surgery. 
Person–time incidence rates for revision surgery were 
calculated by dividing the count of revision replacements 
by the cumulative time with primary implant.
All-cause mortality rates taken from the ONS data were 
applied to this population to generate the number of 
implant-years for each interval—ie, the period of exposure 
to potential revision surgery (eg, 100 patients with 
1·0% mortality would generate 99 implant-years for the 
first year interval). All-cause mortality and annual 
incidence rates were applied as multiple decrements at 
1-year intervals. The total number of counts for predicted 
revisions was summed and divided by the population to 
produce an estimate of lifetime risk for patients undergoing 
surgery between the ages of 50 and 100 years (in 5-year age 
bands for ages 50–54 years through to 85 years and older).
Revision incidence rates were also applied to the 
censored (ie, implant in situ at the end of the study period) 
and lost-to-follow-up populations to generate an adjusted 
revision–incidence (lost and censored population) which 
was also then adjusted for ONS mortality rates in the 
same way. Lifetime risk of revision surgery was calculated 
by grouping the 1-year intervals into 5-year age-bands.23 
An actuarial life-table method was applied, as previously 
described, to a hypothetical population of the same 
magnitude as the subgroup under investigation. Count 
data for incidence of revision surgery was assumed to be a 
count-random variable and as such a Poisson distribution 
was used to calculate 95% CI.17 Smoothed hazard plots 
showing instantaneous risk of revision (risk of revision 
following a given period of implant survival) were 
generated for both sexes.
All statistical analyses were done with Stata (Statacorp. 
2014; Stata Statistical Software: release version IC 13.1. 
College Station, Texas, USA) and Microsoft Excel 2011 
(Microsoft Corporation, Redmond, WA).
The CPRD Group has obtained ethical approval from a 
National Research Ethics Service Committee (NRES) for 
all purely observational research with anonymised CPRD 
data—namely, studies that do not include patient 
involvement. The study has been approved by ISAC 
(Independent Scientific Advisory Committee) for MHRA 
Database Research, protocol number 11_050A.
Role of the funding source
Support was received from the National Institute for 
Health Research (NIHR) Oxford Musculoskeletal 
Biomedical Research Unit, the sponsor had no role in 
study design, data collection, data analysis, data 
interpretation, or report preparation. The corresponding 
author (AJP) had full access to all the data in the study 
6 500 000 patients identified on Clinical Practice Research Datalink
54 276 patients with total knee replacement 63 158 patients with total hip replacement
117 434 patients with complete datasets
117 456 patients identified with primary total hip replacement or 
 total knee replacement codes
Figure 1: trial profile
Female Male Total
Total hip replacement
N (%) 39 289 (62%) 23 869 (38%) 63 158
Mean age in 
years (SD)
70·4 (11·1) 67·7 (11·0) 69·4 (11·1)
Total knee replacement
N (%) 31 682 (59·5%) 22 594 (41·5%) 54 276
Mean age in 
years (SD)
70·7 (9·6) 69·4 (9·4) 70·1 (9·6)
Table 1: Demographic data
Total Implants 
revised
Deaths Lost to 
follow-up 
or 
censored
Cumulative implant 
survival rate (95% CI)
Lost and 
censored 
population 
adjusted 
survival
5 37 066 144 991 4845 0·979 (0·9779–0·9804) 0·977
10 13 203 62 514 2330 0·956 (0·9534–0·9585) 0·950
15 3312 33 158 691 0·910 (0·9029–0·9157) 0·893
20 444 3 19 199 0·850 (0·8323–0·8663) 0·812
Table 2: Patient survival at 5, 10, 15, and 20 years after total hip replacement
See Online for appendix
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and AJP had final responsibility for the decision to 
submit for publication.
Results
Between Jan 1, 1991, and Dec 31, 2011, 117 434 patients 
were identified from the database as having undergone a 
total hip replacement (n=63 158) or total knee replacement 
(n=54 276) during the study period (figure 1). The mean 
age of patients undergoing joint replacement was 
69·4 years (SD 11·1) for hip and 70·1 years (9·6) for knee 
replacement; 15% of patients were aged 50–60 years at 
time of surgery in both the hip and knee replacement 
groups, and 15% were older than 79 years in both groups. 
The number of women undergoing surgery was greater 
for both hip and knee replacement (table 1). Mean total 
hip replacement follow-up was 5·8 years (range 
0·0–23·1, median 4·9), and for total knee replacement 
was 5·2 years (0·0–22·5, 4·5).
10-year implant survival rate was 95·6% (95% CI 
95·3–95·9) and 20-year implant survival rate was 
85% (83·2–86·6) for total hip replacement (table 2). 
10-year implant survival rate was 96·1% (95·8–96·4) and 
20-year rate was 89·7% (87·5–91·5) for total knee 
replacement (table 3). In both types of replacement, 
implant survival over time was higher for female patients 
and older patients (figures 2 and 3, appendix), with the 
lowest implant survival rates seen in patients in their 50s 
at the time of index surgery.
The estimated lifetime risk of revision (LTRR) increased 
with decreasing age at the time of primary surgery for 
both hip and knee replacements (figures 2 and 3). For 
patients aged 70 years at implantation (mean age of 
implantation) the LTRR was between 4·4% and 7·7% 
(highest in male patients with total hip replacement). 
Older than this age, LTRR reduced with time for both hip 
and knee replacement, and was consistent between 
sexes. For patients aged between 60 and 70 years at the 
time of primary surgery, LTRR increased with decreasing 
age, reaching approximately 15% for both hip and knee 
replacement at 60 years, with greater risk in male than in 
female patients. For women between the ages of 50 and 
60 years at primary surgery, the LTRR does not change a 
great deal for total hip replacement and increases by a 
few percentage points for total knee replacement. 
However, a significant increase in LTRR was seen in 
younger men, with values of 29·6% (95% CI 26·6–32·6) 
for hip and 35·0% (30·9–39·1) for knee replacement 
seen for the youngest patient group (50–54 years).
14% (n=22 122) of the study population died during the 
study period, with a mean age of 75·3 years (SD 7·9) at 
time of surgery and a mean age of 80·8 years (SD 8·11) at 
death. Of these patients, 98% (n=21 624) died with their 
primary implant still in situ.
The timing of revision surgery shows a peak incidence 
within 5 years of primary implantation in all age ranges, 
with a mean time to revision surgery of 6·56 years 
(95% CI 6·05–7·08) in hip and 4·55 (4·07–5·02) in knee 
replacement for patients aged 50–59 years at initial 
surgery and 4·08 (3·73–4·39) for hip and 3·57 
(3·26–3·88) for knee replacement in their eighth decade. 
The smoothed hazard plots in figures 4 and 5 show 
consistently higher revision risks for men and younger 
patients at all timepoints. These graphs also show that 
the trends of timing to revision surgery are similar 
across all age bands, with the exception of the most 
Total Implants 
revised
Deaths Lost to 
follow-up 
or 
censored
Cumulative implant survival 
rate (95% CI)
Lost and 
censored 
population 
adjusted 
survival
5 30 056 89 1427 5648 0·9798 (0·9784–0·9812) 0·977
10 8261 25 495 2128 0·9612 (0·9583–0·9639) 0·953
15 1717 12 155 523 0·9294 (0·9217–0·9364) 0·912
20 152 0 12 72 0·8969 (0·8745–0·9154) 0·862
Table 3: Patient survival at 5, 10, 15, and 20 years after total knee replacement
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Figure 2: Lifetime risk of revision after total hip replacement
Plot showing estimates of lifetime risk of total hip replacement revision against age at the time of total hip replacement 
primary surgery (in 5-year age bands) and stratified by sex (results adjusted for lost and censored population).
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Figure 3: Lifetime risk of revision after total knee replacement
Plot showing estimates of lifetime risk of total knee replacement revision against age at the time of primary total knee 
replacement surgery (in 5-year age bands) and stratified by sex (results adjusted for lost and censored population).
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elderly patient groups, in whom follow-up is limited by 
life expectancy.
The mean annual rate of patients lost to follow-up 
(excluding censored patients) is 2·2% for total hip 
replacement (95% CI 2·0–2·4) and 1·8% for total knee 
replacement (1·7–2·0). Adjustment for these lost and 
censored patients increased the estimate of LTRR 
similarly in each age group.
The lost and censored subpopulations were analysed at 
a number of timepoints and found to be consistently of 
the same demographics as the remaining population for 
that period.
Discussion
Our results show that for patients who are younger than 
60 years at primary surgery, their lifetime risk of revision 
increases significantly, reaching up to one in three 
in those patients aged 50–55 years. These figures are in 
contrast to older patients for whom our data show that 
for patients undergoing hip or knee replacement at or 
over 70 years of age, the lifetime risk of requiring revision 
surgery is between 1% and 6%; this estimate applies to 
about half of patients undergoing this type of surgery. 
Time to revision surgery reaches a peak around 5 years 
after implantation, with over half of revisions occurring 
within 6 years after primary surgery for all age groups. 
As far as we are aware this is the first time this 
methodology has been applied to joint replacement 
revision surgery and it emphasises the dramatic effect 
age has on risk of revision after surgery.
Our data are supported by previously published data in 
this area where an increased revision rate in younger 
patients has been identified.3,24,25 However, most 
population studies that specifically address this issue are 
based on 10-year follow-up data from registries. In fact, 
no previous studies have quantified the risk of revision 
over the patient’s life and examined when revision is 
likely to be done. Our study not only highlights a lifetime 
revision risk for patients under 60 years at intervention 
of up to 35%, with risk of revision higher than in other 
age-groups at all timepoints, but also that the time to 
revision in many cases is within 5 years, which itself 
carries an increased re-revision risk. 3 As a result, young 
patients are likely to spend many more years than 
previously expected with a revision implant, which 
carries with it poor outcomes.26
We noted that sex has a significant influence on the 
estimated lifetime revision rate for both total hip 
replacement and total knee replacement. Below 
age 70 years, men have a consistently higher estimated 
LTRR. The effects are seen most dramatically in the 
youngest age group (50–55 years) in whom LTRR for 
men is 24% after total knee replacement, about 1·7 times 
greater than for women undergoing the same procedure, 
with similar trend after total hip replacement. These 
same trends are also demonstrated by the smoothed 
hazard plots (figures 4 and 5) with the instantaneous risk 
of revision in these groups being raised at all timepoints.
Although no information exists for lifetime risk data 
for revision joint replacement, the technique has been 
previously used to study primary joint replacement for 
hip and knee osteoarthritis; lifetime risk for the 
development of osteoarthritis is estimated at 25% for the 
hip and 45% for the knee18 and lifetime risk of undergoing 
total hip replacement is 11·6% for women and 7·1% for 
men, and for total knee replacement 10·8% for women 
and 8·1% for men.17
As well as presenting the novel use of lifetime revision 
estimates, we also did implant survival analysis on the 
CPRD dataset. This analysis allowed us to compare and 
validate our data against published work from the joint 
registries that use the same methodology. The UK 
National Joint Registry (UK NJR) published figures for 
10-year revision risk were 5·75% for total hip and 4·47% 
for total knee replacement, which showed similar results 
as the implant survival analysis results in this study 
(5·0% for hip and 4·7% for knee replacement),3 with 
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Figure 4: Smoothed hazard curve of revision risk in female patients by age
Instantaneous risk of revision for a given length of implant survival, stratified by age at time of primary total hip 
replacement or total knee replacement (in 10-year age-bands).
Figure 5: Smoothed hazard curve of revision risk in male patients by age
Instantaneous risk of revision for a given length of implant survival, stratified by age at time of primary total hip 
replacement or total knee replacement (in 10-year age-bands).
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similar trends for reducing implant survival in patients 
aged under 60 years over a 10-year period. However, we 
believe our data suggest that 10-year implant survival does 
underestimate the scale of the problem for the younger 
patient. For instance, in a patient with a 10-year life 
expectancy, an estimate of the potential 10-year survival of 
the implant provides good insight into the likely chance 
of undergoing revision. However, for a patient under 
60 years, who might live for another 30–40 years, 10-year 
implant survival could underestimate exposure to the real 
risk of revision. A much more representative figure is the 
estimate of lifetime risk (in this case based on a dataset 
with up to 20 years’ follow-up).
The study has some limitations. It focuses on implant 
survival as an indicator of successful outcome after joint 
replacement; we acknowledge that a patient’s outcome 
after surgery is more complex than this simple measure. 
Patient reported outcomes, morbidity data, and mortality 
data are equally as important to patients. Ideally, data for 
these factors and LTRR would all be available to patients 
who are deciding whether or not to undergo surgery. 
Lifetime risk estimates in this large population study 
might be affected by the smaller numbers in the 
stratified age and sex subgroups in the final follow-up 
periods. As such, where appropriate, our estimates were 
based on 15-year follow-up data to maintain population 
subgroup size.
This study does not include data relating to the 
indication for surgery or implant type (including 
metal-on-metal or ceramic bearing surfaces), whereas 
evidence exists that these factors can contribute to 
variations in implant survival.3,7 To limit these effects, 
patients under the age of 50 years were excluded to avoid 
including the more complex pathology seen in younger 
patients who require surgery. An analysis of annual 
revision rates across the 20-year follow-up period was 
consistent, suggesting the effect of changing trends in 
implant use was minimal. Laterality data for each patient 
was not available, nor was coding for previous 
contralateral procedure. Although this omission should 
not have a large effect on the lifetime risk estimations, it 
was not possible to adjust for bilateral disease as a 
potential risk factor for revision. The first chronological 
codes for primary surgery and revision were consistently 
taken for each patient, and this might have underestimated 
how quickly these patients underwent revision.
The lifetime risk calculation is a standard method 
permitting multiple decrements to account for competing 
risks (all-cause mortality), but it does not afford the 
flexibility of model-based methods in dealing with 
predictor variables. In this study, the lifetime risk 
calculation is based on follow-up data of up to 20 years, 
and could underestimate the revision rates seen, especially 
in younger patients in whom predicted life-expectancy 
exceeds 20 years. The use of all-cause mortality data from 
the ONS does not account for the reduced mortality rates 
seen in patients presenting for joint replacement 
compared with the general population,27 and might 
overestimate mortality rates and subsequently over-
estimate LTRR estimates.
The study also showed that some patients were lost to 
follow-up; these patients were subsequently accounted for 
and reintroduced into the population after having the 
same revision incidence applied to them found at the time 
they left the study, and the same principle was applied to 
censored patients. Previous studies have advocated treating 
patients in these loss-to-follow-up groups with higher 
failure rates than those seen in the surveyed population; 
this is often the consequence of analysis of single-centre 
series. The nature of the CRPD is such that patients are 
lost to follow-up if they move geographical location and 
subsequently out of the catchment of their primary care 
practice; census data suggest people are more likely to 
move when medically well. Given the nature of the CPRD 
population, care should be taken when extrapolating these 
results to other populations in which health-care 
behaviours and practices differ from those in the UK.
However, the strength of this study is its population-level 
data and subsequently large sample. In addition, the 
CPRD represents a large population dataset selected to be 
representative of the UK as a whole;21 as a consequence, 
results derived from this dataset will be less at risk of 
confounding factors often found in smaller datasets and 
those collected from smaller regions where local factors 
(including demographic, socioeconomic, and referral 
thresholds) could vary.
This work sheds new light on the risk of revision 
surgery for patients younger than age 60 years. Although 
it has been previously established that this group of 
patients have a higher 10-year revision rate than patients 
older than 60 years, we believe that the true risk to 
patients is much higher than previously thought. For 
patients under 60 years of age, the lifetime risk of 
revision increases to a third, with the highest levels of 
revision seen in men between the ages of 50–55 years. 
These higher lifetime risks are paired with higher risks 
of revision at all timepoints and short mean times to 
revision, meaning a patient in their 50s with a potential 
life expectancy of more than 30 years could spend many 
years living with a revision joint replacement with limited 
functional ability. On a broader level with the numbers of 
joint replacements increasing year on year this issue will 
create a significant health economic burden for any 
health-care system.28 In patients older than 60 years at 
first intervention, the risk of revision decreases and by 
age 70 years the likelihood of revision surgery in some 
patients is less than 1 in 20. In this age group, 95% of 
patients will retain their prosthesis, suggesting that long 
term revision rates are not as high as they seem to be.3,29
At a personal level these new data have significant 
implications for patients younger than age 60, who should 
consider the possibility of living with a revision procedure 
for many years if they undergo total hip replacement or 
total knee replacement and subsequently require early 
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revision. Patients who are considering undergoing joint 
replacement should balance the potential benefits of an 
improvement in their quality of life against the potential 
risks of the intervention: death, medical complications, 
infection, poor functional outcome, and the need for 
revision surgery. Patients have indicated that they require 
improved information about these outcomes, particularly 
in relation to deciding on the correct time to have surgery. 
A patient’s age and sex affect these outcomes and therefore 
might influence their decision. Patients are most often 
informed about risk of revision in terms of the likely 
10-year survival of their implant, which can be an abstract 
and potentially confusing idea.20 To be able to answer 
these concerns in as accurate and clear a form as possible 
is important to provide useful information to aid patient 
decision making. We believe that an estimate of the 
lifetime risk of revision is likely to be a valuable addition to 
the decision making process, and is particularly relevant 
given the findings of this study, in which differences in 
outcome highlight the requirement for a more 
personalised approach to estimating potential risks and 
benefits for patients who are considering this procedure.
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